Homeopathic Medicines in Third (Omicron) Wave of COVID-19: Prognostic Factor Research

IF 1.2 4区医学 Q3 INTEGRATIVE & COMPLEMENTARY MEDICINE

Homeopathy Pub Date : 2023-12-29 DOI:10.1055/s-0043-1776758

{"title":"Homeopathic Medicines in Third (Omicron) Wave of COVID-19: Prognostic Factor Research","authors":"","doi":"10.1055/s-0043-1776758","DOIUrl":null,"url":null,"abstract":"Background With the emergence of new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, such as the Omicron variant, during the third wave of the coronavirus disease 2019 (COVID-19) pandemic, there was a need to identify useful homeopathic medicines. This study aimed to identify such medicines and their indications using prognostic factor research (PFR). Methods This was an open-label, multi-centred observational study conducted in January 2022, on confirmed COVID-19 cases. The data were collected from integrated COVID Care Centres in Delhi, India, where homeopathic medicines were prescribed along with conventional treatment. Only those cases that met a set of selection criteria were considered for analysis. The likelihood ratio (LR) was calculated for the frequently occurring symptoms of the frequently prescribed medicines. An LR of 1.3 or greater was considered meaningful. Results Out of the 362 COVID-19 cases, 263 cases were selected for analysis after applying selection criteria. Common symptoms included fatigue, cough, sore throat, myalgia and headache. Twenty-one medicines were prescribed, of which nine medicines – Gelsemium sempervirens, Bryonia alba, Hepar sulphuris, Rhus toxicodendron, Pulsatilla nigricans, Arsenicum album, Belladonna, Nux vomica and Phosphorus – were frequently used. By calculating LRs, the study identified meaningful indications for these medicines. Conclusion Homeopathic medicines have shown promising results in the third wave of COVID-19 as an adjunct therapy. The medicines that were used in the first and second waves were found useful in the third wave also, and their indications were analogous to those found in the earlier waves. Certain new indications of some medicines were elicited in this wave, which warrant further research. However, it is important not to restrict to these medicines only and to continue data collection on COVID-19 in future waves for the improvement of the COVID-19 mini-repertory.","PeriodicalId":13227,"journal":{"name":"Homeopathy","volume":null,"pages":null},"PeriodicalIF":1.2000,"publicationDate":"2023-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Homeopathy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1055/s-0043-1776758","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INTEGRATIVE & COMPLEMENTARY MEDICINE","Score":null,"Total":0}

引用次数: 0

Abstract

Background With the emergence of new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, such as the Omicron variant, during the third wave of the coronavirus disease 2019 (COVID-19) pandemic, there was a need to identify useful homeopathic medicines. This study aimed to identify such medicines and their indications using prognostic factor research (PFR). Methods This was an open-label, multi-centred observational study conducted in January 2022, on confirmed COVID-19 cases. The data were collected from integrated COVID Care Centres in Delhi, India, where homeopathic medicines were prescribed along with conventional treatment. Only those cases that met a set of selection criteria were considered for analysis. The likelihood ratio (LR) was calculated for the frequently occurring symptoms of the frequently prescribed medicines. An LR of 1.3 or greater was considered meaningful. Results Out of the 362 COVID-19 cases, 263 cases were selected for analysis after applying selection criteria. Common symptoms included fatigue, cough, sore throat, myalgia and headache. Twenty-one medicines were prescribed, of which nine medicines – Gelsemium sempervirens, Bryonia alba, Hepar sulphuris, Rhus toxicodendron, Pulsatilla nigricans, Arsenicum album, Belladonna, Nux vomica and Phosphorus – were frequently used. By calculating LRs, the study identified meaningful indications for these medicines. Conclusion Homeopathic medicines have shown promising results in the third wave of COVID-19 as an adjunct therapy. The medicines that were used in the first and second waves were found useful in the third wave also, and their indications were analogous to those found in the earlier waves. Certain new indications of some medicines were elicited in this wave, which warrant further research. However, it is important not to restrict to these medicines only and to continue data collection on COVID-19 in future waves for the improvement of the COVID-19 mini-repertory.

查看原文本刊更多论文

COVID-19 第三（Omicron）波中的顺势疗法药物：预后因素研究

背景随着严重急性呼吸系统综合征冠状病毒 2（SARS-CoV-2）病毒新变种（如 Omicron 变种）在 2019 年冠状病毒病（COVID-19）第三波大流行中的出现，有必要确定有用的顺势疗法药物。本研究旨在利用预后因素研究（PFR）确定此类药物及其适应症。方法这是一项开放标签、多中心观察性研究，于 2022 年 1 月针对 COVID-19 确诊病例开展。数据收集自印度德里的 COVID 综合护理中心，该中心在提供常规治疗的同时还提供顺势疗法药物。只有符合一系列选择标准的病例才会被考虑用于分析。针对常用处方药的常发症状计算了似然比 (LR)。似然比大于或等于 1.3 即为有效。结果在 COVID-19 的 362 个病例中，有 263 个病例在应用选择标准后被选中进行分析。常见症状包括疲劳、咳嗽、咽喉痛、肌痛和头痛。处方药物有 21 种，其中 9 种为常用药，包括半枝莲、白藓皮、硫酸牛黄、毒玫瑰、白头翁、砒霜、颠茄、牛黄和磷。通过计算 LRs，研究确定了这些药物有意义的适应症。结论顺势疗法药物作为辅助疗法在 COVID-19 第三波治疗中显示出良好的效果。在第一波和第二波中使用过的药物在第三波中也被认为是有用的，其适应症与前几波中发现的相似。这次调查还发现了一些药物的新适应症，值得进一步研究。然而，重要的是不能仅局限于这些药物，而应在今后的波次中继续收集 COVID-19 的数据，以改进 COVID-19 小病历。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Homeopathy 医学-全科医学与补充医学

CiteScore

3.40

自引率

70.60%

发文量

审稿时长

20.1 weeks

期刊介绍： Homeopathy is an international peer-reviewed journal aimed at improving the fundamental understanding and clinical practice of homeopathy by publishing relevant high-quality original research articles, reviews, and case reports. It also promotes commentary and debate on matters of topical interest in homeopathy.